{"id":44159,"date":"2022-05-20T11:01:01","date_gmt":"2022-05-20T09:01:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/"},"modified":"2022-05-20T11:01:01","modified_gmt":"2022-05-20T09:01:01","slug":"global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/","title":{"rendered":"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5589926\/proliferative-vitreoretinopathy-pvr-drugs-in?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=39gt39&amp;utm_campaign=1701777+-+Global+Proliferative+Vitreoretinopathy+(PVR)+Drugs+Pipeline+Guide+2022&amp;utm_exec=cari18prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.\n<\/p>\n<p>\nIt provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy, complete with analysis by stage of development, drug target, mechanism of action, route of administration and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\n<\/p>\n<p>\nThe pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.\n<\/p>\n<p>\nThe guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.\n<\/p>\n<p>\n<strong>Scope<\/strong>\n<\/p>\n<ul>\n<li>\nThe pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) .\n<\/li>\n<li>\nThe pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities\/research institutes based on information derived from company and industry-specific sources.\n<\/li>\n<li>\nThe pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.\n<\/li>\n<li>\nThe pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&amp;D brief, MoA &amp; other developmental activities.\n<\/li>\n<li>\nThe pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects.\n<\/li>\n<li>\nThe pipeline guide evaluates Proliferative Vitreoretinopathy (PVR) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.\n<\/li>\n<li>\nThe pipeline guide encapsulates all the dormant and discontinued pipeline projects.\n<\/li>\n<li>\nThe pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Overview<\/strong>\n<\/p>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Therapeutics Development<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Overview\n<\/li>\n<li>\nPipeline by Companies\n<\/li>\n<li>\nPipeline by Universities\/Institutes\n<\/li>\n<li>\nProducts under Development by Companies\n<\/li>\n<li>\nProducts under Development by Universities\/Institutes\n<\/li>\n<\/ul>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Therapeutics Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nAssessment by Target\n<\/li>\n<li>\nAssessment by Mechanism of Action\n<\/li>\n<li>\nAssessment by Route of Administration\n<\/li>\n<li>\nAssessment by Molecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Companies Involved in Therapeutics Development<\/strong>\n<\/p>\n<ul>\n<li>\nAldeyra Therapeutics Inc\n<\/li>\n<li>\nAptitude Medical Systems Inc\n<\/li>\n<li>\nFocal Point Pharmaceuticals Inc\n<\/li>\n<li>\nNovartis AG\n<\/li>\n<li>\nPanag Pharma Inc\n<\/li>\n<li>\nRactigen Therapeutics Inc\n<\/li>\n<\/ul>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Drug Profiles<\/strong>\n<\/p>\n<ul>\n<li>\nAptamers to Inhibit PDGF for Proliferative Vitreoretinopathy &#8211; Drug Profile\n<\/li>\n<li>\nmethotrexate &#8211; Drug Profile\n<\/li>\n<li>\nOM-101 &#8211; Drug Profile\n<\/li>\n<li>\nonternabez &#8211; Drug Profile\n<\/li>\n<li>\nRAG-1C &#8211; Drug Profile\n<\/li>\n<li>\nSmall Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy &#8211; Drug Profile\n<\/li>\n<li>\nXOMA-089 &#8211; Drug Profile\n<\/li>\n<\/ul>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Dormant Projects<\/strong>\n<\/p>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Product Development Milestones<\/strong>\n<\/p>\n<p>\n<strong>List of Tables<\/strong>\n<\/p>\n<ul>\n<li>\nNumber of Products under Development for Proliferative Vitreoretinopathy (PVR), 2022\n<\/li>\n<li>\nNumber of Products under Development by Companies, 2022\n<\/li>\n<li>\nNumber of Products under Development by Universities\/Institutes, 2022\n<\/li>\n<li>\nProducts under Development by Companies, 2022\n<\/li>\n<li>\nProducts under Development by Universities\/Institutes, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Target, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Mechanism of Action, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Route of Administration, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Molecule Type, 2022\n<\/li>\n<li>\nProliferative Vitreoretinopathy (PVR) &#8211; Pipeline by Aldeyra Therapeutics Inc, 2022\n<\/li>\n<li>\nProliferative Vitreoretinopathy (PVR) &#8211; Pipeline by Aptitude Medical Systems Inc, 2022\n<\/li>\n<li>\nProliferative Vitreoretinopathy (PVR) &#8211; Pipeline by Focal Point Pharmaceuticals Inc, 2022\n<\/li>\n<li>\nProliferative Vitreoretinopathy (PVR) &#8211; Pipeline by Novartis AG, 2022\n<\/li>\n<li>\nProliferative Vitreoretinopathy (PVR) &#8211; Pipeline by Panag Pharma Inc, 2022\n<\/li>\n<li>\nProliferative Vitreoretinopathy (PVR) &#8211; Pipeline by Ractigen Therapeutics Inc, 2022\n<\/li>\n<\/ul>\n<p>\n<strong>Proliferative Vitreoretinopathy (PVR) &#8211; Dormant Projects, 2022<\/strong>\n<\/p>\n<p>\n<strong>List of Figures<\/strong>\n<\/p>\n<ul>\n<li>\nNumber of Products under Development for Proliferative Vitreoretinopathy (PVR), 2022\n<\/li>\n<li>\nNumber of Products under Development by Companies, 2022\n<\/li>\n<li>\nNumber of Products by Targets, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Targets, 2022\n<\/li>\n<li>\nNumber of Products by Mechanism of Actions, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Mechanism of Actions, 2022\n<\/li>\n<li>\nNumber of Products by Routes of Administration, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Routes of Administration, 2022\n<\/li>\n<li>\nNumber of Products by Molecule Types, 2022\n<\/li>\n<li>\nNumber of Products by Stage and Molecule Types, 2022<\/p>\n<p>\n\u00a0\n<\/p>\n<p>\n\u00a0\n<\/p>\n<\/li>\n<\/ul>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAldeyra Therapeutics Inc\n<\/li>\n<li>\nAptitude Medical Systems Inc\n<\/li>\n<li>\nFocal Point Pharmaceuticals Inc\n<\/li>\n<li>\nNovartis AG\n<\/li>\n<li>\nPanag Pharma Inc\n<\/li>\n<li>\nRactigen Therapeutics Inc<\/p>\n<p>\n\u00a0\n<\/p>\n<p>\n\u00a0\n<\/p>\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5589926\/proliferative-vitreoretinopathy-pvr-drugs-in?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=39gt39&amp;utm_campaign=1701777+-+Global+Proliferative+Vitreoretinopathy+(PVR)+Drugs+Pipeline+Guide+2022&amp;utm_exec=cari18prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/4c4a50<\/a>\n<\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong>\n<\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;&#x6f;:&#112;&#114;&#x65;&#x73;&#x73;&#64;r&#101;&#x73;&#x65;&#x61;rc&#104;&#97;&#x6e;&#x64;&#x6d;a&#114;&#107;&#x65;&#x74;&#x73;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#x65;&#115;&#x73;&#x40;&#114;&#x65;&#x73;&#101;&#x61;&#x72;&#99;&#x68;&#x61;&#110;&#x64;&#x6d;&#97;&#x72;&#x6b;&#101;&#x74;&#x73;&#46;&#x63;&#x6f;m<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape. It provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy, complete with &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44159","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape. It provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy, complete with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-20T09:01:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-05-20T09:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/\"},\"wordCount\":876,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005146\\\/en\\\/1462399\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/\",\"name\":\"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005146\\\/en\\\/1462399\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-05-20T09:01:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005146\\\/en\\\/1462399\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005146\\\/en\\\/1462399\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape. It provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy, complete with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-20T09:01:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 &#8211; ResearchAndMarkets.com","datePublished":"2022-05-20T09:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/"},"wordCount":876,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/","name":"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/21\/logo.jpg","datePublished":"2022-05-20T09:01:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220520005146\/en\/1462399\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-proliferative-vitreoretinopathy-pvr-drugs-pipeline-guide-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44159"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44159\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}